Video

What’s next for sacral neuromodulation in OAB patients with Parkinson’s disease?

Author(s):

Urology Times staff

“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.

In this video, Sarah Martin, DO, discusses the take-home message from the recent Neurourology & Urodynamics study, “Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review,” for which she served as first author. Martin is an FPMRS fellow at Glickman Urological & Kidney Institute at Cleveland Clinic.

Related Videos
Raveen Syan, MD, FPMRS, answers a question during a video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
J. Quentin Clemens, MD, MSCI, answers a question during a video interview
Timothy Lyon, MD, answers a question during a video interview
Anne Pelletier Cameron, MD, FRCSC, FPMRS, answers a question during a video interview
Related Content
ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures
January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke
Functional success was achieved in 58% of patients at 5-year follow-up.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
December 26th 2024

Top 10 BPH articles and videos of 2024

Benjamin P. Saylor
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
December 17th 2024

Sexual QOL improved at 12 months following AUS placement

LeRoy Jones, MD
"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD.
FDA greenlights pivotal trial of wearable bioelectronic device for OAB
December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke
The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.
© 2025 MJH Life Sciences

All rights reserved.